Nicergoline-13C,d3

Nicergoline-13C,d3

• UNSPSC Description: Nicergoline-13C,d3 is the 13C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].
• Target Antigen: Adrenergic Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease; Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(OC[C@H](C[C@]12OC)CN([13C]([2H])([2H])[2H])[C@]2([H])CC3=CN(C)C4=C3C1=CC=C4)C5=CN=CC(Br)=C5
• Molecular Weight: 488.40
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Alvarez-Guerra, M., N. Bertholom, and R.P. Garay, Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat. Fundam Clin Pharmacol, 1999. 13(1): p. 50-8.|[3]Mizuno T, et, al. Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res. 2005 Dec 20;1066(1-2):78-85.|[4]Zang G, et, al. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease. Mol Med Rep. 2018 May;17(5):7293-7300.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported